Clinical trial
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating…
NCT00498979 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00498979 |
|---|---|
| Title | Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers |
| Official title | Phase I Evaluation of Sodium Stibogluconate in Combination With Interferon α-2b Followed by Cisplatin, Vinblastine and Dacarbazine for Patients With Melanoma or Malignancies Potentially Responsive to SSG and/or Interferons |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Stage IV Melanoma |
| Intervention type | Biological, Drug |
| Interventions | recombinant interferon alfa-2b, cisplatin, sodium stibogluconate, dacarbazine, vinblastine |
| Enrollment | 22 |
| Start date | May 1, 2007 |
| Primary completion | May 1, 2010 |
| Completion | Jan 1, 2012 |
| First posted | Jul 11, 2007 |
| Last update posted | Jul 24, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: